Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Investigating Platelet Alpha Degranulation Defect in Patients with Gaucher Disease Using Immunofluorescence-Microscopy on Peripheral Blood Smears

Shoshana Revel-Vilk, Dafna Frydman, Ari Zimran, Ellen Broide, Elinore Molad, Emmanuel Benayoun, Mira Naamad

Blood (2024) 144 (Supplement 1): 5414.

https://doi.org/10.1182/blood-2024-207259

Published: 2024

Journal Articles

Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)

Majdolen Joleen Istaiti, Katie Thoren, Shoshana Revel-Vilk, Ari Zimran, Ola Landgren

Blood (2024) 144 (Supplement 1): 3294.

https://doi.org/10.1182/blood-2024-194457

Published: 2024

Journal Articles

Cancer Risk in Patients with Gaucher Disease Using Real-World Data

Shoshana Revel-Vilk, Ari Zimran, Majdolen Istaiti, Orly Manor, Varda Shalev, Litat Azani, Gabriel Chodick, Ora Paltiel

Blood (2023) 142 (Supplement 1): 488.

https://doi.org/10.1182/blood-2023-179459

Published: 2023

Journal Articles

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Shoshana Revel-Vilk, MD, Tama Dinur, PhD, Majdolen Istaiti, Dafna Frydman, DMV, Michal Becker-Cohen, MSc, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4712.

https://doi.org/10.1182/blood-2019-123000

Published: 2019

Journal Articles

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Shoshana Revel-Vilk, MD, Jeffrey Szer, MBBS, Michal Becker Cohen, Ari Zimran, MD

Blood (2019) 134 (Supplement_1): 4862.

https://doi.org/10.1182/blood-2019-131013

Published: 2019

Journal Articles

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

David J. Kuter, MD DPhil, Michael Wajnrajch, MD MPA, Betina Hernandez, MD, Rong Wang, MPH, Raul Chertkoff, MD MBA, Ari Zimran, MD

Blood (2018) 132 (Supplement 1): 3755.

https://doi.org/10.1182/blood-2018-99-112660

Published: 2018

Journal Articles

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Ari Zimran, MD, Shoshana Revel-Vilk, MD, Deborah Elstein, PhD, Naama Arbel, Michal Becker-Cohen, MSc, Gaya Chicco, Jeff Szer, MB, BS, FRACP

Blood (2017) 130 (Supplement 1): 2101.

https://doi.org/10.1182/blood.V130.Suppl_1.2101.2101

Published: 2017

Journal Articles

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

M. Judith Peterschmitt, MD, Elena Lukina, PhD, MD, Nora Watman, MD, Marta Dragosky, M.D., Gregory M Pastores, Elsa Avila Arreguin, M.D., Hanna Rosenbaum, MD, Ari Zimran, MD, Elena Sysoeva, Rasha Aguzzi, Leorah H Ross, Ana Cristina Puga, M.D.

Blood (2012) 120 (21): 1038.

https://doi.org/10.1182/blood.V120.21.1038.1038

Published: 2012

Journal Articles

Preimplantation Genetic Diagnosis for Benign Hematological Disorders Combined with HLA Matching and Stem Cells Development.

Gheona Altarescu, Deborah Elstein, Ari Zimran, MD, Talia Eldar Geva, Ephrat Levy Lahad, Paul Renbaum

Blood (2012) 120 (21): 3167.

https://doi.org/10.1182/blood.V120.21.3167.3167

Published: 2012

Journal Articles

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Ari Zimran, MD, Derlis Emilio Gonzalez-Rodriguez, MD, Aya Abrahamov, MD, Deborah Elstein, PhD, Rene Heitner, MD, Alona Paz, MD, Einat Brill-Almon, PhD, Raul Chertkoff, MD

Blood (2012) 120 (21): 2140.

https://doi.org/10.1182/blood.V120.21.2140.2140

Published: 2012

Journal Articles

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood . 2011;118(22): 5767–5773 .

Blood (2012) 119 (19): 4577.

https://doi.org/10.1182/blood-2012-01-408054

Published: 2012

Journal Articles

Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Blood (2011) 118 (22): 5767–5773.

https://doi.org/10.1182/blood-2011-07-366955

Published: 2011

Journal Articles

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

David J. Kuter, MD, DPhil, Atul Mehta, MD, Carla Hollak, MD, PhD, Pilar Giraldo, MD, PhD, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Nadia Belmatoug, MD, Monika Brand, Audrey Muller, Berthold Schaaf, Ruben Giorgino, Ari Zimran, MD

Blood (2011) 118 (21): 3207.

https://doi.org/10.1182/blood.V118.21.3207.3207

Published: 2011

Journal Articles

Gaucher Disease and LGL Proliferations: Provocative Commonality?

Rosa Ruchlemer, MD, Deborah Elstein, PhD, Eti Broide, Constantine Reinus, Hannah Maayaan, Ari Zimran, MD

Blood (2011) 118 (21): 1100.

https://doi.org/10.1182/blood.V118.21.1100.1100

Published: 2011

Journal Articles

How I treat Gaucher disease

Ari Zimran

Blood (2011) 118 (6): 1463–1471.

https://doi.org/10.1182/blood-2011-04-308890

Published: 2011

Journal Articles

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Maria D. Cappellini, MD, Nadia Belmatoug, Alex Cole, Stephan vom Dahl, Patrick Deegan, Jack Goldblatt, Barry E. Rosenbloom, MD, Anna Tylki-Szymañska, Neal J. Weinreb, MD, Ari Zimran, MD, Carla Hollak, MD, PhD

Blood (2010) 116 (21): 4719.

https://doi.org/10.1182/blood.V116.21.4719.4719

Published: 2010

Journal Articles

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

Ari Zimran, Gheona Altarescu, Mici Philips, Drorit Attias, Marina Jmoudiak, Maher Deeb, Nan Wang, Kiran Bhirangi, Gabriel M. Cohn, Deborah Elstein

Blood (2010) 115 (23): 4651–4656.

https://doi.org/10.1182/blood-2010-02-268649

Published: 2010

Journal Articles

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement

Deborah Elstein, Altoon Dweck, Drorit Attias, Irith Hadas-Halpern, Shoshana Zevin, Gheona Altarescu, Johannes F. M. G. Aerts, Sonja van Weely, Ari Zimran

Blood (2007) 110 (7): 2296–2301.

https://doi.org/10.1182/blood-2007-02-075960

Published: 2007

Journal Articles

Response: Correlation between Gaucher disease clinical severity and surrogate markers is weak

Ari Zimran, Deborah Elstein, Ernest Beutler

Blood (2007) 109 (1): 387–388.

https://doi.org/10.1182/blood-2006-07-034439

Published: 2007

Journal Articles

Platelet Adhesion Defect Is Common in Gaucher Disease.

Batia Roth, MD, Galia Ronen, MD, Dror Rosengarten, MD, Alexander Brill, MD,PhD, Shoshana Vilk, MD, Tony Futerman, PhD, Swetlana Boldin-Adamsky, PhD, Ari Zimran, MD, David Varon, MD

Blood (2006) 108 (11): 1105.

https://doi.org/10.1182/blood.V108.11.1105.1105

Published: 2006

NARROW

Investigating Platelet Alpha Degranulation Defect in Patients with Gaucher Disease Using Immunofluorescence-Microscopy on Peripheral Blood Smears

Excess Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Screened Cohort of Patients with Gaucher Disease (GD)

Cancer Risk in Patients with Gaucher Disease Using Real-World Data

Not All Patients with Mild Phenotype of Gaucher Disease (GD) Need Disease Specific Treatment As Reflected By Patients Reported Outcomes Measures

Bone Marrow Involvement in Patients with Type 1 Gaucher Disease Receiving Low-Dose Long Term Enzyme Replacement Therapy (median 18 years)

Open-Label, Expanded Access Study of Taliglucerase Alfa in Patients with Gaucher Disease Requiring Enzyme Replacement Therapy

Reduction in Intravenous Infusion Duration of Enzyme Replacement Therapy to Ten Minutes with Velaglucerase Alfa in Adult Patients with Type 1 Gaucher Disease

Eliglustat, an Investigational Oral Therapy for Gaucher Disease Type 1: Phase 2 Results After 4 Years of Treatment

Preimplantation Genetic Diagnosis for Benign Hematological Disorders Combined with HLA Matching and Stem Cells Development.

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease.

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood . 2011;118(22): 5767–5773 .

Pivotal trial with plant cell–expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Miglustat Therapy in Type 1 Gaucher Disease: Long-Term Treatment Experience From a Multicenter, Retrospective Cohort Study,

Gaucher Disease and LGL Proliferations: Provocative Commonality?

How I treat Gaucher disease

Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4–5 Years

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement

Response: Correlation between Gaucher disease clinical severity and surrogate markers is weak

Platelet Adhesion Defect Is Common in Gaucher Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only